CA3166653A1 - Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue - Google Patents

Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue

Info

Publication number
CA3166653A1
CA3166653A1 CA3166653A CA3166653A CA3166653A1 CA 3166653 A1 CA3166653 A1 CA 3166653A1 CA 3166653 A CA3166653 A CA 3166653A CA 3166653 A CA3166653 A CA 3166653A CA 3166653 A1 CA3166653 A1 CA 3166653A1
Authority
CA
Canada
Prior art keywords
cxcl8
inhibitor
cancer
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3166653A
Other languages
English (en)
French (fr)
Inventor
Marcello Allegretti
Pieradelchi RUFFINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Publication of CA3166653A1 publication Critical patent/CA3166653A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3166653A 2020-02-21 2021-02-19 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue Pending CA3166653A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20158787.0 2020-02-21
EP20158787.0A EP3868369A1 (en) 2020-02-21 2020-02-21 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
PCT/EP2021/054231 WO2021165510A1 (en) 2020-02-21 2021-02-19 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue

Publications (1)

Publication Number Publication Date
CA3166653A1 true CA3166653A1 (en) 2021-08-26

Family

ID=69723868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3166653A Pending CA3166653A1 (en) 2020-02-21 2021-02-19 Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue

Country Status (7)

Country Link
US (1) US20230090111A1 (https=)
EP (2) EP3868369A1 (https=)
JP (1) JP2023519491A (https=)
AU (1) AU2021222360A1 (https=)
CA (1) CA3166653A1 (https=)
IL (1) IL294722A (https=)
WO (1) WO2021165510A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
PL1776336T3 (pl) 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2021165510A1 (en) 2021-08-26
JP2023519491A (ja) 2023-05-11
AU2021222360A1 (en) 2022-09-01
IL294722A (en) 2022-09-01
US20230090111A1 (en) 2023-03-23
EP4106739A1 (en) 2022-12-28
EP3868369A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
CN115297862A (zh) 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合
JP6528779B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
CN1929845A (zh) Pdeⅲ抑制剂用于降低患有心力衰竭的哺乳动物的心脏大小的用途
EA014055B1 (ru) Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
CA2906196A1 (en) Enantiomerically enriched s-oxprenolol compositions for treating cancer
JP7590351B2 (ja) Ｐｒｍｔ５阻害剤を使用した癌の治療法
WO2022217060A1 (en) Cancer treatment using parp inhibitors and plk1 inhibitors
KR20070095930A (ko) 항종양제
CN103930113B (zh) 用于预防和治疗非小细胞肺癌的包含吡嗪并三嗪衍生物的组合物
WO2023093663A1 (en) Pharmaceutical composition and use thereof
RU2832833C1 (ru) Ингибитор cxcl8 и его фармацевтическая композиция для применения при лечении усталости, связанной с раком
CA3166653A1 (en) Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue
EP3967310B1 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
CA2684174C (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
JP2003277265A (ja) ｅＮＯＳ発現に起因する疾患の予防または治療薬
WO2024059962A1 (en) Pharmaceutical composition and use thereof
US10857113B2 (en) Bezafibrate for the treatment of cancer
JP5830983B2 (ja) 抗癌剤の副作用軽減剤
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
US20250319068A1 (en) Treatment of diseases via administration of buntanetap and an antihypertensive agent
CN1660434A (zh) 抗恶性肿瘤的药物组合物及其应用
JP2020519581A (ja) 肥満細胞疾患の処置のための方法及び医薬組成物
WO2025248485A1 (en) Pharmaceutical compositions and methods of use thereof
WO2024023766A1 (en) P13k inhibitor combination therapy
CN121941509A (zh) 用于治疗恶性肿瘤的RXRα调节剂

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250107

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250107

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250428

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250428

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250826

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260402